Bayer to seek approval for menopausal relief drug after third trial win
Positive topline results from Phase III long-term study OASIS 3 support submissions for marketing authorization for Bayer’s elinzanetant
Bayer’s $425M non-hormonal therapy for menopause symptoms clears first PhIII test
Bayer’s elinzanetant meets key secondary endpoints in Phase III studies
Bayer starts Phase II study NIRVANA to evaluate elinzanetant
Phase IIb Clinical Study of Investigational Compound Elinzanetant Evaluated Efficacy and Safety in Postmenopausal Patients with Vasomotor Symptoms Study Findings Published in Menopause: The Journal of The North American Menopause Society
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a global leader in women’s healthcare, announced that it will extend the Phase III clinical development program OASIS by initiating OASIS 4 – a Phase III non-US study in breast cancer patients and women at risk for breast cancer with vasomotor symptoms caused by endocrine therapy.
Bayer has added another clinical trial to its extensive phase 3 programme for oral neurokinin antagonist elinzanetant, hoping to show that it can treat vasomotor symptoms (VMS) in breast cancer patients.
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a global leader in women’s healthcare, announced today that it started the Phase III clinical development program OASIS, which aims to evaluate the efficacy and safety of the investigational compound, elinzanetant for the treatment of vasomotor symptoms during menopause. elinzanetant is currently under development as a potential non-hormonal, once-daily, oral, dual neurokinin-1,3 receptor antagonist.